Health & TechA two-drug combo before surgery cut bladder cancer deaths by 42%
In the 695-patient phase 3 VOLGA trial, published in NEJM and co-led by UCLA, durvalumab plus enfortumab vedotin before bladder removal raised two-year survival to 78.4 percent from 69.4 percent for patients who cannot take cisplatin. AstraZeneca funded the study.
Verified · UCLA Health
